Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Tyrosine Kinase

Tyrosine Kinase

Products for  Tyrosine Kinase

  1. Cat.No. Product Name Information
  2. GC19187 H3B-6527 H3B-6527 (H3 Biomedicine) is a highly selective FGFR4 inhibitor with potent antitumour activity in FGF19 amplified cell lines and mice. H3B-6527 Chemical Structure
  3. GC12461 HA-100 (hydrochloride) inhibitor of protein kinases (PKs) HA-100 (hydrochloride) Chemical Structure
  4. GC30762 Harmine (Telepathine) A unique regulator of PPARγ expression Harmine (Telepathine) Chemical Structure
  5. GC38413 Harmine hydrochloride Harmine hydrochloride Chemical Structure
  6. GC15674 HDS 029 HDS 029 (compound 29) is a potent tyrosine kinase inhibitor with IC50s of 0.3, 1.1, 0.5, 2.5, 24 nM for erbB1, erbB2, erbB4, EGF, HER, respectively. HDS 029 Chemical Structure
  7. GC30767 Heparan Sulfate

    Heparan sulfate (HS) is a complex, polyanionic polysaccharide ubiquitously expressed on cell surfaces and in the extracellular matrix.

     Heparan Sulfate Chemical Structure
  8. GC15000 Herbimycin A antibiotic,Src family kinase inhibitor Herbimycin A Chemical Structure
  9. GC13098 HG-10-102-01 LRRK2 inhibitor HG-10-102-01 Chemical Structure
  10. GC36222 HG-14-10-04 An ALK inhibitor HG-14-10-04 Chemical Structure
  11. GC50660 HIOC HIOC is a potent and selective activator of TrkB (tropomyosin related kinase B) receptor. HIOC Chemical Structure
  12. GC65134 HIV-IN-6 HIV-IN-6 is a HIV-Ⅰ viral replication inhibitor by targeting Src family kinases (SFK) that interact with Nef protein of the virus, such as Hck. HIV-IN-6 Chemical Structure
  13. GC14259 HKI 357 irreversible inhibitor of ErbB2 (HER2) and EGFR HKI 357 Chemical Structure
  14. GC63507 HM43239 HM43239 is an orally active and selective FLT3 inhibitor with IC50s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively. HM43239 inhibits the kinase activity of FLT3 as a reversible type I inhibitor and modulates p-STAT5, p-ERK, SYK, JAK1/2, and TAK1. HM43239 inhibits the proliferation and induces the apoptosis of leukemic cells. HM43239 Chemical Structure
  15. GC14654 HNGF6A increases glucose stimulated insulin secretion and glucose metabolism HNGF6A Chemical Structure
  16. GC13988 HNMPA cell impermeable tyrosine kinase inhibitor HNMPA Chemical Structure
  17. GC33053 HS-10296 hydrochloride Almonertinib (HS-10296) hydrochloride is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. HS-10296 hydrochloride shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC50: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). HS-10296 hydrochloride is used for the research of the non-small cell lung cancer. HS-10296 hydrochloride Chemical Structure
  18. GC68458 HS-243 HS-243 Chemical Structure
  19. GC65941 HS-276 HS-276 is an orally active, potent and highly selective TAK1 inhibitor, with a Ki of 2.5 nM. HS-276 shows significant inhibition of TAK1, CLK2, GCK, ULK2, MAP4K5, IRAK1, NUAK, CSNK1G2, CAMKKβ-1, and MLK1, with IC50 values of 8.25, 29, 33, 63, 125, 264, 270, 810, 1280, and 5585 nM, respectively. HS-276 can be used for rheumatoid arthritis (RA) research. HS-276 Chemical Structure
  20. GC62429 HS271 HS271 is a highly potent, orally active and selective IRAK4 inhibitor, with an IC50 of 7.2 μM. HS271 Chemical Structure
  21. GC32963 hVEGF-IN-1 hVEGF-IN-1, a quinazoline derivative, could specifically bind to the G-rich sequence in the internal ribosome entry site A (IRES-A) and destabilize the G-quadruplex structure. hVEGF-IN-1 binds to the IRES-A (WT) with a Kd of 0.928 μM in SPR experiments. hVEGF-IN-1 could hinder tumor cells migration and repress tumor growth by decreasing VEGF-A protein expression. hVEGF-IN-1 Chemical Structure
  22. GC43885 Hypothemycin A resorcylic acid lactone polyketide Hypothemycin Chemical Structure
  23. GC63297 I-OMe-Tyrphostin AG 538 I-OMe-Tyrphostin AG 538 (I-OMe-AG 538) is a specific inhibitor of IGF-1R (insulin-like growth factor-1 receptor tyrosine kinase). I-OMe-Tyrphostin AG 538 Chemical Structure
  24. GC17982 Icotinib EGFR tyrosine kinase inhibitor Icotinib Chemical Structure
  25. GC16244 Icotinib Hydrochloride An EGFR inhibitor Icotinib Hydrochloride Chemical Structure
  26. GC15647 ID-8 DYRK inhibitor ID-8 Chemical Structure
  27. GC63606 iHCK-37 iHCK-37 (ASN05260065) is a potent and specific Hck inhibitor with a Ki value of 0.22 μM. iHCK-37 Chemical Structure
  28. GC12370 IKK-16 (hydrochloride) IκB kinases (IKKs) inhibitor IKK-16 (hydrochloride) Chemical Structure
  29. GC12180 IKK-16 (IKK Inhibitor VII) IKK-16 (IKK Inhibitor VII) is a selective IκB kinase (IKK) inhibitor for IKK2, IKK complex and IKK1 with IC50s of 40 nM, 70 nM and 200 nM, respectively. IKK-16 (IKK Inhibitor VII) Chemical Structure
  30. GC34159 Ilorasertib (ABT-348) Ilorasertib (ABT-348) (ABT-348) is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib (ABT-348) also is a potent VEGF, PDGF inhibitor. Ilorasertib (ABT-348) has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Ilorasertib (ABT-348) Chemical Structure
  31. GC38519 Ilorasertib hydrochloride Ilorasertib (ABT-348) hydrochloride is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib hydrochloride also is a potent VEGF, PDGF inhibitor. Ilorasertib hydrochloride has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Ilorasertib hydrochloride Chemical Structure
  32. GC10314 Imatinib (STI571) Imatinib (STI571) (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib (STI571) also is an inhibitor of SARS-CoV and MERS-CoV. Imatinib (STI571) Chemical Structure
  33. GC60930 Imatinib D4 Imatinib D4 (STI571 D4) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib D4 Chemical Structure
  34. GC39612 Imatinib D8 Imatinib D8 (STI571 D8) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib D8 Chemical Structure
  35. GC15263 Imatinib hydrochloride V-Abl/c-Kit/PDGFR inhibitor Imatinib hydrochloride Chemical Structure
  36. GC11759 Imatinib Mesylate (STI571) Imatinib Mesylate (STI571) (STI571 Mesylate) is a tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50=100 nM) tyrosine kinases. Imatinib Mesylate (STI571) Chemical Structure
  37. GC47452 Imatinib-d3 Imatinib-d3 (STI571-d3) hydrochloride is the deuterium labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV. Imatinib-d3 Chemical Structure
  38. GC48614 IMP-1710 A clickable UCH-L1 inhibitor IMP-1710 Chemical Structure
  39. GC17866 INCB28060 INCB28060 (INC280; INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). INCB28060 can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. INCB28060 potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. INCB28060 is largely metabolized by CYP3A4 and aldehyde oxidase. INCB28060 Chemical Structure
  40. GC36311 Indirubin Derivative E804 Indirubin Derivative E804 is a potent inhibitor of Insulin-like Growth Factor 1 Receptor (IGF1R), with an IC50 of 0.65 μM for IGF1R. Indirubin Derivative E804 Chemical Structure
  41. GC16126 INDY

    Dyrk1A and Dyrk1B inhibitor, selective

     INDY Chemical Structure
  42. GC48387 Inostamycin A A bacterial metabolite with anticancer activity Inostamycin A Chemical Structure
  43. GC52472 Inostamycin A (sodium salt) A bacterial metabolite with anticancer activity Inostamycin A (sodium salt) Chemical Structure
  44. GC18093 Insulin (human) recombinant expressed in yeast

    Endogenous insulin receptor agonist

     Insulin (human) recombinant expressed in yeast Chemical Structure
  45. GC67998 Insulin degludec Insulin degludec Chemical Structure
  46. GC31526 Insulin levels modulator Insulin levels modulator could be used to treat diabetes. Insulin levels modulator Chemical Structure
  47. GC31303 Insulin(cattle) (Insulin from bovine pancreas) Insulin cattle (Insulin from bovine pancreas) is a two-chain polypeptide hormone produced in vivo in the pancreatic β cells. Insulin(cattle) (Insulin from bovine pancreas) Chemical Structure
  48. GC17158 IRAK inhibitor 1 An IRAK4 inhibitor IRAK inhibitor 1 Chemical Structure
  49. GC12651 IRAK inhibitor 2 IRAK inhibitor 2 Chemical Structure
  50. GC11103 IRAK inhibitor 3 IRAK inhibitor 3 Chemical Structure
  51. GC16264 IRAK inhibitor 4 IRAK inhibitor 4 Chemical Structure
  52. GC36328 IRAK inhibitor 4 trans IRAK inhibitor 4 (trans) is the trans form of IRAK inhibitor 4. IRAK inhibitor 4 trans Chemical Structure
  53. GC17371 IRAK inhibitor 6 An IRAK4 inhibitor IRAK inhibitor 6 Chemical Structure
  54. GC15999 IRAK-1-4 Inhibitor I A benzimidazole IRAK-1-4 Inhibitor I Chemical Structure
  55. GC62583 IRAK-4 protein kinase inhibitor 2 IRAK-4 protein kinase inhibitor 2 (compound 1) is a potent inhibitor of interleukin-1 (IL-1) receptor-associated kinase-4 (IRAK-4), with an IC50 of 4 μM. IRAK-4 protein kinase inhibitor 2 Chemical Structure
  56. GC31688 IRAK4-IN-1 IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor with an IC50 of 7 nM. IRAK4-IN-1 Chemical Structure
  57. GC38799 IRAK4-IN-4 IRAK4-IN-4 is an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor extracted from patent CN107163044A, Compound15, has an IC50 of 2.8 nM. IRAK4-IN-4 Chemical Structure
  58. GC61944 IRAK4-IN-6 IRAK4-IN-6 is an orally efficacious and selective IRAK4 inhibitor with an IC50 of 4 nM, and targetes MyD88 L265P mutant diffuse large B cell lymphoma. IRAK4-IN-6 Chemical Structure
  59. GC13961 ISCK03 inhibitor of SCF-mediated c-kit activation ISCK03 Chemical Structure
  60. GC12167 ITK inhibitor

    Potent ITK inhibitor

     ITK inhibitor Chemical Structure
  61. GC36354 ITK inhibitor 2 ITK inhibitor 2 is a interleukin-2-inducible T-cell kinase (ITK) inhibitor extracted from patent WO2011065402A1, compound 4, with an IC50 of 2 nM. ITK inhibitor 2 Chemical Structure
  62. GC16869 Ixabepilone A broad-spectrum anticancer agent Ixabepilone Chemical Structure
  63. GC62500 JAK2-IN-7 JAK2-IN-7 is a selective JAK2 inhibitor with IC50s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3V617F cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3. JAK2-IN-7 stimulates cell cycle arrest in the G0/G1 phase and induces tumor cellapoptosis. Antitumor activities. JAK2-IN-7 Chemical Structure
  64. GC62665 JAK2/FLT3-IN-1 TFA JAK2/FLT3-IN-1 (TFA) is a potent and orally active dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. JAK2/FLT3-IN-1 (TFA) has anti-cancer activity. JAK2/FLT3-IN-1 TFA Chemical Structure
  65. GC50706 JBJ-03-142-02 JBJ-03-142-02 Chemical Structure
  66. GC62632 JBJ-04-125-02

    JBJ-04-125-02 is a potent, mutant-selective, allosteric and orally active EGFR inhibitor with an IC50 of 0.26 nM for EGFRL858R/T790M. JBJ-04-125-02 can inhibit cancer cell proliferation and EGFRL858R/T790M/C797S signaling. JBJ-04-125-02 has anti-tumor activities.

     JBJ-04-125-02 Chemical Structure
  67. GC67690 JBJ-09-063 hydrochloride

    JBJ-09-063 hydrochloride is a mutation selective allosteric EGFR inhibitor

     JBJ-09-063 hydrochloride Chemical Structure
  68. GC67860 JBJ-09-063 TFA JBJ-09-063 TFA Chemical Structure
  69. GC19205 JH-II-127 JH-II-127 is a highly potent, selective, and brain penetrant LRRK2 inhibitor, with IC50 of 6.6 nM, 2.2 nM ,47.7 nM for LRRK2-wild-type, LRRK2-G2019S, LRRK2-A2016T. JH-II-127 Chemical Structure
  70. GC33062 JH-VIII-157-02 JH-VIII-157-02 is a structural analogue of alectinib, acts as an ALK inhibitor, and shows an IC50 of 2 nM for echinoderm microtubule-associated protein-like 4-ALK (EML4-ALK) G1202R in cells. JH-VIII-157-02 Chemical Structure
  71. GC63925 JH-X-119-01 JH-X-119-01 is a potent and selective interleukin-1 receptor-associated kinases 1 (IRAK1) inhibitor. JH-X-119-01 Chemical Structure
  72. GC18168 JI-101

    An orally active inhibitor

     JI-101 Chemical Structure
  73. GC65436 JND3229 JND3229 is a reversible EGFRC797S inhibitor with IC50 values of 5.8, 6.8 and 30.5 nM for EGFRL858R/T790M/C797S, EGFRWT and EGFRL858R/T790M, respectively. JND3229 has good anti-proliferative activity and can effectively inhibit tumour growth in vivo. JND3229 can be used in cancer research, especially in non-small cell carcinoma. JND3229 Chemical Structure
  74. GC18030 JNJ 28871063 hydrochloride ErbB receptor family inhibitor JNJ 28871063 hydrochloride Chemical Structure
  75. GC38502 JNJ-10198409 A potent PDGF tyrosine kinase inhibitor JNJ-10198409 Chemical Structure
  76. GC14544 JNJ-10198409 inhibitor of platelet-derived growth factor (PDGF-BB) tyrosine kinase JNJ-10198409 Chemical Structure
  77. GC12585 JNJ-38877605 C-Met inhibitor,ATP-competitive JNJ-38877605 Chemical Structure
  78. GC33266 JNJ-38877618 JNJ-38877618 is a potent, highly selective, orally bioavailable Met kinase inhibitor with IC50s of 2 and 3 nM for wild type and mutant Met, respectively. JNJ-38877618 Chemical Structure
  79. GC32995 JNJ-47117096 hydrochloride (MELK-T1 hydrochloride) JNJ-47117096 hydrochloride (MELK-T1 hydrochloride) is potent and selective MELK inhibitor, with an IC50 of 23 nM, also effectively inhibits Flt3, with an IC50 of 18 nM. JNJ-47117096 hydrochloride (MELK-T1 hydrochloride) Chemical Structure
  80. GC11362 K 252a A protein kinase inhibitor K 252a Chemical Structure
  81. GN10497 Kaempferitrin Kaempferitrin Chemical Structure
  82. GC17638 KB SRC 4 KB SRC 4 is a potent, and highly selective c-Src inhibitor, with a Ki of 44 nM and a Kd of 86 nM, and shows no inhibition on c-Abl up to 125 μM; KB SRC 4 has antitumor activity. KB SRC 4 Chemical Structure
  83. GC32625 KDR-in-4 KDR-in-4 (KDR-in-4) is a potent kinase insert domain-containing receptor (KDR/VEGFR2) inhibitor with an IC50 of 7 nM. KDR-in-4 Chemical Structure
  84. GC63943 KH-CB20 KH-CB20, an E/Z mixture, is a potent and selective inhibitor of CLK1 and the closely related isoform CLK4, with an IC50 of 16.5 nM for CLK1. KH-CB20 Chemical Structure
  85. GC13264 Ki20227 A c-Fms kinase inhibitor Ki20227 Chemical Structure
  86. GC11666 Ki8751 VEGFR-2 inhibitor,potent and selective Ki8751 Chemical Structure
  87. GC13902 KRCA 0008 Ack1 and anaplastic lymphoma kinase (ALK) dual inhibitor KRCA 0008 Chemical Structure
  88. GC12590 KRN 633 VEGFR inhibitor,ATP-competitive KRN 633 Chemical Structure
  89. GC10626 KU14R KU14R Chemical Structure
  90. GC14592 KW 2449 A multi-kinase inhibitor KW 2449 Chemical Structure
  91. GC10523 KX1-004 Pp60c-src inhibitor KX1-004 Chemical Structure
  92. GC14288 KX2-391 KX2-391 (KX2-391) is an inhibitor of Src that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. KX2-391 Chemical Structure
  93. GC10222 KX2-391 dihydrochloride A Src kinase inhibitor KX2-391 dihydrochloride Chemical Structure
  94. GC50137 KYL KYL, an antagonistic peptide, selectively targets EphA4 receptor. KYL Chemical Structure
  95. GC32044 L 601920-0 (Methyl-3β-hydroxycholenate) L 601920-0 (Methyl-3β-hydroxycholenate) is a ROR gamma modulator extracted from patent US20110263046 A1, in figure 2. L 601920-0 (Methyl-3β-hydroxycholenate) Chemical Structure
  96. GC44085 L-Sulforaphene L-Sulforaphene, isolated from radish seeds, exhibits an ED50 against velvetleaf seedlings approximately 2 x 10-4 M. L-Sulforaphene promotes cancer cells apoptosis and inhibits migration via inhibiting EGFR, p-ERK1/2, NF‐κB and other signals. L-Sulforaphene Chemical Structure
  97. GC36423 Lanraplenib A Syk inhibitor Lanraplenib Chemical Structure
  98. GC38630 Lanraplenib succinate Lanraplenib succinate (GS-9876 succinate) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib succinate Chemical Structure
  99. GC13608 Lapatinib A dual inhibitor of EGFR and ErbB2 Lapatinib Chemical Structure
  100. GC25559 Lapatinib (GW-572016) Ditosylate Lapatinib (GW-572016) Ditosylate is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib (GW-572016) Ditosylate Chemical Structure
  101. GC16593 Lapatinib Ditosylate Lapatinib Ditosylate is a selective dual inhibitor of ErbB-2 and EGFR with IC50 value against ErbB-2 and EGFR of 9.2 and 10.8 nM in vitro, respectively. Lapatinib Ditosylate Chemical Structure

Items 501 to 600 of 1115 total

per page
  2. 4
  3. 5
  4. 6
  5. 7
  6. 8

Set Descending Direction